Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study
- 22 November 2010
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (1), 79-86
- https://doi.org/10.1185/03007995.2010.536527
Abstract
Granulocyte colony stimulating factors (G-CSFs) decrease the incidence of febrile neutropenia (FN) in cancer patients receiving myelosuppressive chemotherapy. There are two G-CSFs (pegfilgrastim and filgrastim) that differ in dosing schedules from which oncologists may prescribe. This study aimed to compare the effectiveness of prophylactic pegfilgrastim and filgrastim on the risk of hospitalizations. The secondary objective was to compare the effectiveness of the timing of initiation (prophylactic versus delayed). A retrospective study of administrative claims from US commercial payers included adult patients with Non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008. For these patients, the first course of chemotherapy and each unique cycle with use of G-CSF was identified and designated 'prophylaxis' if used within the first 5 days of each cycle, or 'delayed', if after day 5. The risk of neutropenia-related and all-cause hospitalization was evaluated for the pegfilgrastim and filgrastim prophylaxis cohorts and for the prophylaxis and delayed G-CSF initiation cohorts. Among 5,571 patient-cycles identified, 88.9% and 11.1% used pegfilgrastim and filgrastim respectively. The rate of neutropenic hospitalization was 1.1% for pegfilgrastim prophylaxis and 3.5% for filgrastim prophylaxis (P = 0.001). Compared to chemotherapy cycles with filgrastim prophylaxis, those with pegfilgrastim prophylaxis had decreased risk of neutropenia-related (adjusted odds ratio (OR) = 0.38, 95% confidence interval (CI) 0.17-0.83) and all-cause hospitalization (adjusted OR = 0.51, 95% CI 0.31-0.84). The neutropenic hospitalization rate was 1.2% for G-CSF prophylactic initiation and 3.7% for delayed G-CSF initiation (P < 0.001). Chemotherapy cycles with prophylactic initiation of either G-CSF had decreased risk of neutropenia-related (adjusted OR = 0.34, 95% CI 0.21-0.56) and all-cause hospitalization (adjusted OR = 0.67, 95% CI 0.49-0.91) compared with delayed initiation of G-CSF. Pegfilgrastim prescribed as prophylaxis resulted in lower risk of neutropenia-related and all-cause hospitalizations compared to filgrastim prophylaxis. This reduction was similar for prophylactic G-CSF initiation when compared to delayed G-CSF initiation.Keywords
This publication has 12 references indexed in Scilit:
- Impact of Asthma Controller Medications on Clinical, Economic, and Patient-Reported OutcomesMayo Clinic Proceedings, 2009
- Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort studyClinical Therapeutics, 2009
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic ReviewJournal of Clinical Oncology, 2007
- Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology PracticesJournal of Managed Care Pharmacy, 2007
- Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin’s Lymphoma (United States)Cancer Causes & Control, 2006
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Are Shorter Courses of Filgrastim Prophylaxis Associated with Increased Risk of Hospitalization?Annals of Pharmacotherapy, 2006
- Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2004
- A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyAnnals of Oncology, 2003
- Estimating Causal Effects from Large Data Sets Using Propensity ScoresAnnals of Internal Medicine, 1997